Form 8-K - Current report:
SEC Accession No. 0001140361-25-023362
Filing Date
2025-06-23
Accepted
2025-06-23 16:29:21
Documents
14
Period of Report
2025-06-20
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ny20050862x1_8k.htm   iXBRL 8-K 62344
2 EXHIBIT 3.1 ny20050862x1_ex3-1.htm EX-3.1 9425
3 EXHIBIT 10.1 ny20050862x1_ex10-1.htm EX-10.1 307859
  Complete submission text file 0001140361-25-023362.txt   572433

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA bbio-20250620.xsd EX-101.SCH 3868
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbio-20250620_lab.xml EX-101.LAB 22691
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbio-20250620_pre.xml EX-101.PRE 16554
17 EXTRACTED XBRL INSTANCE DOCUMENT ny20050862x1_8k_htm.xml XML 4386
Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38959 | Film No.: 251065283
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)